These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34702567)

  • 1. Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
    Walter A; Rocconi RP; Monk BJ; Herzog TJ; Manning L; Bognar E; Wallraven G; Aaron P; Horvath S; Tang M; Stanbery L; Coleman RL; Nemunaitis J
    Gynecol Oncol; 2021 Dec; 163(3):459-464. PubMed ID: 34702567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
    Rocconi RP; Monk BJ; Walter A; Herzog TJ; Galanis E; Manning L; Bognar E; Wallraven G; Stanbery L; Aaron P; Senzer N; Coleman RL; Nemunaitis J
    Gynecol Oncol; 2021 Jun; 161(3):676-680. PubMed ID: 33715892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy.
    Sliheet E; Robinson M; Morand S; Choucair K; Willoughby D; Stanbery L; Aaron P; Bognar E; Nemunaitis J
    Cancer Gene Ther; 2022 Jul; 29(7):993-1000. PubMed ID: 34785763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
    Rocconi RP; Grosen EA; Ghamande SA; Chan JK; Barve MA; Oh J; Tewari D; Morris PC; Stevens EE; Bottsford-Miller JN; Tang M; Aaron P; Stanbery L; Horvath S; Wallraven G; Bognar E; Manning L; Nemunaitis J; Shanahan D; Slomovitz BM; Herzog TJ; Monk BJ; Coleman RL
    Lancet Oncol; 2020 Dec; 21(12):1661-1672. PubMed ID: 33271095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials.
    Zhang Y; Zhang L; Zhao Y; Wang S; Feng L
    Front Oncol; 2022; 12():945867. PubMed ID: 36338747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.
    Rocconi RP; Stanbery L; Tang M; Madeira da Silva L; Walter A; Monk BJ; Herzog TJ; Coleman RL; Manning L; Wallraven G; Horvath S; Bognar E; Senzer N; Brun S; Nemunaitis J
    Commun Med (Lond); 2022; 2():106. PubMed ID: 36051466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer.
    Barve M; Aaron P; Manning L; Bognar E; Wallraven G; Horvath S; Stanbery L; Nemunaitis J
    Clin Med Insights Oncol; 2022; 16():11795549221110501. PubMed ID: 35957960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
    Oh J; Barve M; Matthews CM; Koon EC; Heffernan TP; Fine B; Grosen E; Bergman MK; Fleming EL; DeMars LR; West L; Spitz DL; Goodman H; Hancock KC; Wallraven G; Kumar P; Bognar E; Manning L; Pappen BO; Adams N; Senzer N; Nemunaitis J
    Gynecol Oncol; 2016 Dec; 143(3):504-510. PubMed ID: 27678295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer.
    Rocconi RP; Stanbery L; Madeira da Silva L; Barrington RA; Aaron P; Manning L; Horvath S; Wallraven G; Bognar E; Walter A; Nemunaitis J
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680].
    Rocconi RP; Monk BJ; Walter A; Herzog TJ; Galanis E; Manning L; Bognar E; Wallraven G; Stanbery L; Aaron P; Senzer N; Coleman RL; Nemunaitis J
    Gynecol Oncol; 2023 Feb; 169():173. PubMed ID: 36456375
    [No Abstract]   [Full Text] [Related]  

  • 11. Clonal Neoantigen: Emerging "Mechanism-based" Biomarker of Immunotherapy Response.
    Nemunaitis J; Stanbery L; Willoughby D; Bognar E; Brun S; Walter A; Monk BJ; Rocconi RP; Choucair K; Coleman RL
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.
    Rocconi RP; Stevens EE; Bottsford-Miller JN; Ghamande SA; Elder J; DeMars LL; Munkarah A; Aaron P; Stanbery L; Wallraven G; Bognar E; Manley M; Horvath S; Manning L; Walter A; Galanis E; Herzog T; Monk BJ; Coleman RL; Nemunaitis J
    Cancer Gene Ther; 2022 Mar; 29(3-4):369-382. PubMed ID: 33753870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?
    Levine MD; O'Malley DM; Haight PJ; Senter L; Wagner V; Bixel KL; Cohn DE; Copeland LJ; Cosgrove CM; McLaughlin EM; Backes FJ
    Gynecol Oncol Rep; 2023 Apr; 46():101173. PubMed ID: 37082521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy.
    Nemunaitis J; Stanbery L; Walter A; Wallraven G; Nemunaitis A; Horvath S; Bognar E; Rao D; Engle S; Brun S; Ghisoli M; Rocconi RP; Monk BJ; Coleman RL
    Future Oncol; 2024; 20(29):2149-2164. PubMed ID: 39101448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis.
    Kaneko M
    Ann Pharmacother; 2022 Jan; 56(1):27-34. PubMed ID: 33926263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
    Yi T; Feng Y; Sundaram R; Tie Y; Zheng H; Qian Y; You D; Yi T; Wang P; Zhao X
    Int J Cancer; 2019 Sep; 145(5):1209-1220. PubMed ID: 30666631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
    Mirza MR; Monk BJ; Herrstedt J; Oza AM; Mahner S; Redondo A; Fabbro M; Ledermann JA; Lorusso D; Vergote I; Ben-Baruch NE; Marth C; Mądry R; Christensen RD; Berek JS; Dørum A; Tinker AV; du Bois A; González-Martín A; Follana P; Benigno B; Rosenberg P; Gilbert L; Rimel BJ; Buscema J; Balser JP; Agarwal S; Matulonis UA;
    N Engl J Med; 2016 Dec; 375(22):2154-2164. PubMed ID: 27717299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
    Ray-Coquard I; Pautier P; Pignata S; Pérol D; González-Martín A; Berger R; Fujiwara K; Vergote I; Colombo N; Mäenpää J; Selle F; Sehouli J; Lorusso D; Guerra Alía EM; Reinthaller A; Nagao S; Lefeuvre-Plesse C; Canzler U; Scambia G; Lortholary A; Marmé F; Combe P; de Gregorio N; Rodrigues M; Buderath P; Dubot C; Burges A; You B; Pujade-Lauraine E; Harter P;
    N Engl J Med; 2019 Dec; 381(25):2416-2428. PubMed ID: 31851799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
    Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cella D; Meunier J; Goble S; Cameron T; Maloney L; Mörk AC; Bedel J; Ledermann JA; Coleman RL
    J Clin Oncol; 2020 Oct; 38(30):3494-3505. PubMed ID: 32840418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.